Truist Securities Reiterates Rating on Evolent Health, Inc. $EVH
Key Points
- Truist Securities now rates Evolent Health, Inc. ($EVH) "buy" with a $7.00 target.
- The Street's average $EVH price target is $5.88 (Buy).
- $EVH last traded around $4.68.
Truist Securities reiterated its rating on Evolent Health, Inc. ($EVH) to a "buy" rating, with a price target of $7.00 in a recent research note.
Evolent Health, Inc. ($EVH) Stock
Evolent Health, Inc. Earnings
Analysts Set New Price Targets
About Evolent Health, Inc.
Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides Machinify Auth Intelligence, an artificial intelligence tool to aid nurses and physicians in completing clinical review of prior authorization requests. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.